Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

CAPR

Capricor Therapeutics (CAPR)

Capricor Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CAPR
DateHeureSourceTitreSymboleSociété
14/06/202422h31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CAPRCapricor Therapeutics Inc
11/06/202415h25GlobeNewswire Inc.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA PathwayNASDAQ:CAPRCapricor Therapeutics Inc
04/06/202415h00GlobeNewswire Inc.Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
15/05/202423h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CAPRCapricor Therapeutics Inc
14/05/202415h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CAPRCapricor Therapeutics Inc
13/05/202422h05GlobeNewswire Inc.Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
09/05/202415h15GlobeNewswire Inc.Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:CAPRCapricor Therapeutics Inc
08/05/202415h00GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Scientific and Medical ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
06/05/202415h00GlobeNewswire Inc.Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13NASDAQ:CAPRCapricor Therapeutics Inc
24/04/202415h00GlobeNewswire Inc.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
21/03/202413h30GlobeNewswire Inc.Capricor Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:CAPRCapricor Therapeutics Inc
11/03/202413h30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CAPRCapricor Therapeutics Inc
29/02/202422h05GlobeNewswire Inc.Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:CAPRCapricor Therapeutics Inc
27/02/202414h30GlobeNewswire Inc.Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular DystrophyNASDAQ:CAPRCapricor Therapeutics Inc
22/02/202414h30GlobeNewswire Inc.Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29NASDAQ:CAPRCapricor Therapeutics Inc
20/02/202414h30GlobeNewswire Inc.Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward CommercializationNASDAQ:CAPRCapricor Therapeutics Inc
16/02/202423h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CAPRCapricor Therapeutics Inc
24/01/202415h15GlobeNewswire Inc.Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2NASDAQ:CAPRCapricor Therapeutics Inc
04/01/202423h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
17/10/202322h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CAPRCapricor Therapeutics Inc
29/09/202323h02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CAPRCapricor Therapeutics Inc
29/09/202323h00Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:CAPRCapricor Therapeutics Inc
07/09/202300h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CAPRCapricor Therapeutics Inc
15/06/202323h27Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CAPRCapricor Therapeutics Inc
13/06/202323h21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CAPRCapricor Therapeutics Inc
17/05/202301h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CAPRCapricor Therapeutics Inc
12/05/202315h01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CAPRCapricor Therapeutics Inc
17/04/202323h02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CAPRCapricor Therapeutics Inc
17/03/202322h02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CAPRCapricor Therapeutics Inc
31/01/202312h02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CAPRCapricor Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CAPR